Difference between revisions of "Inflammatory myofibroblastic tumor"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "=Guidelines=" to "=Guidelines= '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.ncbi.nlm.nih.gov/pmc" to "https://www.ncbi.nlm.nih.gov/pmc") |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 12: | Line 12: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
| − | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
| − | == | + | ==NCCN== |
| − | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/ | + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma].'' |
=All lines of therapy= | =All lines of therapy= | ||
==Crizotinib monotherapy {{#subobject:d700c4|Regimen=1}}== | ==Crizotinib monotherapy {{#subobject:d700c4|Regimen=1}}== | ||
| Line 24: | Line 24: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5947833/ Gambacorti-Passerini et al. 2018 (PROFILE 1013)] |
|2011-03 to 2013-10 | |2011-03 to 2013-10 | ||
| style="background-color:#ffffbe" |Phase 1b, fewer than 20 pts in this subgroup (RT) | | style="background-color:#ffffbe" |Phase 1b, fewer than 20 pts in this subgroup (RT) | ||
| Line 35: | Line 35: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| − | *[[Crizotinib (Xalkori)]] 250 mg PO twice per day | + | *[[Crizotinib (Xalkori)]] 250 mg PO twice per day on days 1 to 21 |
| − | ''' | + | '''21-day cycles''' |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | #'''PROFILE 1013:''' Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018 May;93(5):607-614. Epub 2018 Feb 8. [https://doi.org/10.1002/ajh.25043 link to original article] [ | + | #'''PROFILE 1013:''' Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018 May;93(5):607-614. Epub 2018 Feb 8. [https://doi.org/10.1002/ajh.25043 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5947833/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29352732/ PubMed] [https://clinicaltrials.gov/study/NCT01121588 NCT01121588] |
[[Category:Inflammatory myofibroblastic tumor regimens]] | [[Category:Inflammatory myofibroblastic tumor regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Soft tissue sarcomas]] | [[Category:Soft tissue sarcomas]] | ||
Latest revision as of 12:08, 23 June 2024
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
Crizotinib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Gambacorti-Passerini et al. 2018 (PROFILE 1013) | 2011-03 to 2013-10 | Phase 1b, fewer than 20 pts in this subgroup (RT) |
Biomarker eligibility criteria
- ALK+
References
- PROFILE 1013: Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018 May;93(5):607-614. Epub 2018 Feb 8. link to original article link to PMC article contains dosing details in manuscript PubMed NCT01121588